COMPARATIVE EFFICACY OF INTERMITTENT AND DAILY DOXAZOSIN THERAPY FOR LUTS ASSOCIATED WITH BPH
Leveillee RJ. Prostate Hyperplasia, Benign. Viewed
September 27, 2008.
M cC o n n ell J D . C o mb in atio n th er ap y s ig n i- ficantly delays progression of benign prostatic hyperplasia. Viewed September 27, 2008.
Roehrborn CG, McConell JD. Etiology, patophy- siology, and natural history of benign prostatic hyperplasi. In: Walsh PC, Retik AB, et al. Eds: Campbell's Urology. 9th ed. Philadelphia: WB. Sauders; 2007. p. 1297-330.
Stanley J, Swierzewski. Benign prostatic hyperplasia
(BPH)/enlarged prostate. Viewed March 6, 2008.
Protocols. Benign prostatic hyperplasia (BPH). Online references for health concerns. Viewed January 10,
Greenstein MA. Enlarged prostate. Medical Encyclo- p e d i a . Vi e w e d J a n u a r y 1 0 , 2 0 0 9 . < w w w. emedicinehealth.com/enlargedprostate/ article>
Kirby R, Lepor H. Evaluation and nonsurgical management of benign prostatic hyperplasia. In: Walsh
PC, et al. Campbell's Urology. 9th ed. 2007. Chapter 87.
Langworth L. Prostate gland enlargement. Viewed 10
Yokoyama T, Watanabe T, Saika T, Nasu Y, Kumon H, Miyaji Y, et al. Natural course of lower urinary tract symptoms following discontinuation of alpha-1- adrenergic blockers in patients with benign prostatic hyperplasia. Int J Urol 2009; 14: 598-601. Viewed September 12, 2009.
Charnow JA. Intermittent therapy may be an option for LUTS. Viewed March 20, 2009.
Jeong HJ, Lee DH. The efficacy of every other day alpha-blocker therapy in men with benign prostatic hyperplasia. Korean J Urol 2005; 46 (4): 366-9.Viewed September 12, 2009
Kaplan SA. Intermittent alpha-blocker therapy in the treatment of men with lower urinary tract symptoms. J Urol 1998; 52 (1).
Yanardag H, Goktas S, Kibar Y, Kilic S, Erduran D. Intermittent tamsulosin therapy in men with lower urinary tract symptoms. J Urol 2005; 1 7 3 : 1 5 5 - 7 . Vi e w e d S e p t e m b e r 1 2 , 2 0 0 9 .
Roehrborn CG, McConnell JD. The management of benign prostatic hyperplasia. Viewed September 12,
McConnell JD, Abrahams P. Evaluation and treatment of LUTS in older men. In: The male urinary tract d y s f u n c t i o n e v a l u a t i o n a n d m a n a g e m e n t . Disampaikan pada 6th International Consultation on New Development in Prostate Cancer and Prostate Disease; 2005.
Jones DA. Benign prostatic hypertrophy and lower urinary tract dysfunction. In: Comprehensive Urology
Rosette JL, Alivizatos G. Guidelines on benign prostatic hyperplasia. In: Guidelines of European Association of Urology; 2008.
Roerig. Cardura (doxazosin mesylate) drug information: Uses, side effects, drug interactions, warnings. Viewed October 20, 2009
Fawzy A. Clinical correlation of maximal urinary flow rate and plasma doxazosin concentrations in the treatment of benign prostatic hyperplasia. Urology 1999; 53: 329-35.
Gillenwater JY, Conn RL, Chrysant SG, Roy J, Gaffney M, Ice K, et al. Doxazosin for the treatment of benign prostatic hyperplasia in patient with mild to moderate essential hypertension, a double-blind, placebo-controlled, dose-response multicenter study. J Urol 1995; 154: 110-5
- There are currently no refbacks.
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.